SIMILAR PATTERNS OF AMINO ACIDS FOR 5YU9_D_1E8D1101_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.83A	5yu9D-1k2pA: 28.8	5yu9D-1k2pA: 14.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 GLY A 272 ASP A 276 LEU A 321 ASP A 332	None	0.79A	5yu9D-1k9aA: 29.7	5yu9D-1k9aA: 12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	5	VAL A 219 ALA A 230 GLY A 286 LEU A 340 ASP A 351	PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-3.6A) PY1 A 700 (-4.4A) PY1 A 700 (-2.7A)	0.47A	5yu9D-1py5A: 24.7	5yu9D-1py5A: 11.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 86 ALA A 99 LYS A 101 MET A 147 ASP A 156 LEU A 201	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 ( 3.4A) None ATP A 535 (-4.8A)	1.10A	5yu9D-1s9iA: 16.2	5yu9D-1s9iA: 15.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 86 ALA A 99 LYS A 101 MET A 147 GLY A 153 LEU A 201 ASP A 212	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 ( 3.4A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.77A	5yu9D-1s9iA: 16.2	5yu9D-1s9iA: 15.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 GLY A 441 CYH A 442 ASP A 445 LEU A 489 ASP A 500	None	0.63A	5yu9D-1snxA: 23.0	5yu9D-1snxA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 377 ALA A 389 LYS A 391 CYH A 442 ASP A 445 ASP A 500	None	0.91A	5yu9D-1snxA: 23.0	5yu9D-1snxA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL X 25 ALA X 37 GLY X 88 ASP X 92 LEU X 137 ASP X 148	STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.5A) None STU X 902 (-4.4A) STU X 902 (-3.6A)	0.82A	5yu9D-2dq7X: 28.9	5yu9D-2dq7X: 13.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	VAL A 281 ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 348 LEU A 393 ASP A 404 LEU A 407	H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) None H8H A 534 (-3.3A) None H8H A 534 (-4.5A) H8H A 534 (-4.2A) None	0.81A	5yu9D-2h8hA: 32.4	5yu9D-2h8hA: 12.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 348 ASP A 404	QUE A 1 (-3.5A) None None QUE A 1 (-3.0A) QUE A 1 ( 4.1A) None	1.07A	5yu9D-2hckA: 30.6	5yu9D-2hckA: 11.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 MET A 314 GLY A 344 ASP A 348 LEU A 393 ASP A 404	QUE A 1 (-3.5A) None QUE A 1 (-3.0A) QUE A 1 ( 4.1A) QUE A 1 (-4.4A) None	0.81A	5yu9D-2hckA: 30.6	5yu9D-2hckA: 11.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 281 ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 404	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 (-3.0A) None	0.98A	5yu9D-2hckA: 30.6	5yu9D-2hckA: 11.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 281 ALA A 293 MET A 314 GLY A 344 LEU A 393 ASP A 404	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.0A) QUE A 1 (-4.4A) None	0.74A	5yu9D-2hckA: 30.6	5yu9D-2hckA: 11.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 259 ALA A 271 GLY A 322 ASP A 326 LEU A 371	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.5A) None 1BM A 499 (-4.4A)	0.49A	5yu9D-2hk5A: 23.7	5yu9D-2hk5A: 19.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2owm	RELATED TO KINESIN-LIKE PROTEIN KIF1C (Neurospora crassa)	PF00225 (Kinesin)	6	VAL A 43 ALA A 387 GLY A 125 ASP A 122 LEU A 163 THR A 153	None	1.37A	5yu9D-2owmA: undetectable	5yu9D-2owmA: 11.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	VAL A 352 ALA A 367 LYS A 369 MET A 390 GLY A 420 LEU A 468 ASP A 479 LEU A 482	ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None ANP A 615 ( 3.9A) ANP A 615 (-4.7A) MG A 614 ( 3.2A) None	0.88A	5yu9D-2ozoA: 30.9	5yu9D-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 352 ALA A 367 LYS A 369 MET A 390 MET A 414 GLY A 420	ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None ANP A 615 ( 3.9A) ANP A 615 ( 3.9A)	1.09A	5yu9D-2ozoA: 30.9	5yu9D-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	VAL A 352 LYS A 369 MET A 390 GLY A 418 LEU A 468 ASP A 479 LEU A 482	ANP A 615 (-4.5A) ANP A 615 (-3.1A) None ANP A 615 ( 4.0A) ANP A 615 (-4.7A) MG A 614 ( 3.2A) None	1.44A	5yu9D-2ozoA: 30.9	5yu9D-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	5	VAL A 33 ALA A 46 GLY A 109 LEU A 156 THR A 166	ATP A 381 (-4.1A) ATP A 381 (-3.5A) None ATP A 381 ( 4.8A) ATP A 381 ( 4.6A)	0.44A	5yu9D-2phkA: 22.1	5yu9D-2phkA: 17.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 495 ALA A 515 LYS A 517 GLY A 570 LEU A 633 ASP A 644	None	0.97A	5yu9D-2psqA: 28.8	5yu9D-2psqA: 13.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	VAL B 55 ALA B 67 LYS B 69 GLY B 120 LEU B 171 THR B 181	None	0.68A	5yu9D-2qkwB: 22.4	5yu9D-2qkwB: 15.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 GLY A 271 ASP A 275 LEU A 328 ASP A 339	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) ADE A 488 ( 4.1A) None ADE A 488 (-4.4A) None	0.64A	5yu9D-2qluA: 24.3	5yu9D-2qluA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 LYS A 217 ASP A 275 LEU A 328 ASP A 339	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None None ADE A 488 (-4.4A) None	0.86A	5yu9D-2qluA: 24.3	5yu9D-2qluA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LYS A 751 MET A 772 LEU A 850 THR A 860 ASP A 861 LEU A 864	GW7 A 1 (-3.9A) GW7 A 1 ( 3.8A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A) GW7 A 1 ( 4.7A)	0.85A	5yu9D-2r4bA: 37.5	5yu9D-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 732 ALA A 749 GLY A 802 LEU A 850 THR A 860 LEU A 864	GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 ( 4.7A)	0.73A	5yu9D-2r4bA: 37.5	5yu9D-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 732 ALA A 749 LYS A 751 LEU A 850 THR A 860 ASP A 861 LEU A 864	GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A) GW7 A 1 ( 4.7A)	0.74A	5yu9D-2r4bA: 37.5	5yu9D-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 234 ALA A 247 GLY A 307 ASP A 311 LEU A 354 THR A 367	XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 ( 3.7A) None XK9 A1511 (-4.6A) XK9 A1511 (-3.7A)	0.54A	5yu9D-2xk9A: 20.8	5yu9D-2xk9A: 14.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 234 ALA A 247 LYS A 249 GLY A 307 ASP A 311 LEU A 354	XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.2A) XK9 A1511 ( 3.7A) None XK9 A1511 (-4.6A)	0.85A	5yu9D-2xk9A: 20.8	5yu9D-2xk9A: 14.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 38 ALA A 51 GLY A 113 ASP A 117 LEU A 160 ASP A 171	None B49 A1294 (-3.2A) B49 A1294 (-3.6A) None B49 A1294 (-4.4A) B49 A1294 (-4.2A)	0.69A	5yu9D-2y7jA: 22.5	5yu9D-2y7jA: 13.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 261 ALA A 273 LYS A 275 GLY A 325 ASP A 329 LEU A 374	None	0.80A	5yu9D-2zv7A: 25.9	5yu9D-2zv7A: 18.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 GLY A 272 ASP A 276 LEU A 321 ASP A 332	None	0.79A	5yu9D-3d7uA: 24.2	5yu9D-3d7uA: 19.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 31 ALA A 44 LYS A 46 MET A 67 ASP A 102 ASP A 164	ANP A 1 (-4.5A) ANP A 1 ( 3.9A) ANP A 1 (-2.8A) None None ANP A 1 (-3.8A)	1.01A	5yu9D-3dakA: 22.7	5yu9D-3dakA: 15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 31 ALA A 44 LYS A 46 MET A 92 ASP A 102 ASP A 164	ANP A 1 (-4.5A) ANP A 1 ( 3.9A) ANP A 1 (-2.8A) None None ANP A 1 (-3.8A)	1.26A	5yu9D-3dakA: 22.7	5yu9D-3dakA: 15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 31 ALA A 44 MET A 67 GLY A 98 LEU A 153 ASP A 164	ANP A 1 (-4.5A) ANP A 1 ( 3.9A) None None None ANP A 1 (-3.8A)	0.84A	5yu9D-3dakA: 22.7	5yu9D-3dakA: 15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dtc	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 158 ALA A 169 GLY A 226 LEU A 275 THR A 293	VIN A6331 (-4.7A) VIN A6331 (-3.4A) VIN A6331 (-3.4A) VIN A6331 (-4.5A) VIN A6331 (-3.6A)	0.47A	5yu9D-3dtcA: 19.6	5yu9D-3dtcA: 14.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	6	VAL A 37 ALA A 50 GLY A 106 LEU A 153 ASP A 167 LEU A 170	None	0.68A	5yu9D-3dxnA: 24.9	5yu9D-3dxnA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	6	VAL A 37 ALA A 50 MET A 100 ASP A 110 LEU A 153 ASP A 167	None	0.97A	5yu9D-3dxnA: 24.9	5yu9D-3dxnA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	6	VAL A 37 ALA A 50 MET A 100 LEU A 153 ASP A 167 LEU A 170	None	0.93A	5yu9D-3dxnA: 24.9	5yu9D-3dxnA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 439 ALA A 455 LYS A 457 GLY A 508 LEU A 556 ASP A 567	AGS A 999 (-4.6A) AGS A 999 (-3.6A) AGS A 999 (-2.5A) None AGS A 999 (-4.5A) AGS A 999 ( 3.9A)	0.94A	5yu9D-3fzpA: 29.9	5yu9D-3fzpA: 18.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3g2f	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 217 ALA A 228 LYS A 230 MET A 279 GLY A 285 LEU A 340	ADP A 900 (-4.3A) ADP A 900 (-3.4A) ADP A 900 (-2.8A) ADP A 900 (-3.6A) ADP A 900 ( 4.2A) ADP A 900 (-4.6A)	0.79A	5yu9D-3g2fA: 24.7	5yu9D-3g2fA: 13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	6	ALA A 247 GLY A 307 ASP A 311 LEU A 354 THR A 367 ASP A 368	None	0.79A	5yu9D-3i6uA: 22.4	5yu9D-3i6uA: 10.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 704 LYS A 723 GLY A 774 ASP A 778 LEU A 822 ASP A 833	ANP A 1 (-3.9A) ANP A 1 (-3.4A) ANP A 1 ( 4.9A) None ANP A 1 (-4.7A) MG A1001 ( 3.1A)	0.81A	5yu9D-3kexA: 30.4	5yu9D-3kexA: 15.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ALA A 719 LYS A 721 MET A 742 GLY A 772 CYH A 773 ASP A 776 LEU A 820 THR A 830 ASP A 831 LEU A 834	ITI A 1 (-2.9A) ITI A 1 (-2.6A) ITI A 1 (-3.4A) ITI A 1 (-3.5A) ITI A 1 (-4.8A) None ITI A 1 (-4.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.6A) None	0.79A	5yu9D-3lzbA: 39.0	5yu9D-3lzbA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL A 702 ALA A 719 LYS A 721 MET A 742 CYH A 773 ASP A 776 LEU A 820 THR A 830 ASP A 831 LEU A 834	ITI A 1 (-4.8A) ITI A 1 (-2.9A) ITI A 1 (-2.6A) ITI A 1 (-3.4A) ITI A 1 (-4.8A) None ITI A 1 (-4.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.6A) None	0.80A	5yu9D-3lzbA: 39.0	5yu9D-3lzbA: 95.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pls	MACROPHAGE-STIMULATI NG PROTEIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1096 ALA A1112 LYS A1114 GLY A1167 ASP A1226 LEU A1229	ANP A1358 (-4.4A) ANP A1358 ( 3.8A) ANP A1358 (-3.2A) None MG A 1 ( 3.2A) None	0.65A	5yu9D-3plsA: 31.3	5yu9D-3plsA: 16.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 734 ALA A 751 MET A 774 GLY A 804 CYH A 805 ASP A 808 LEU A 852 THR A 862	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.5A) 03Q A 1 ( 3.9A) None None 03Q A 1 (-4.4A) 03Q A 1 (-3.3A)	1.33A	5yu9D-3pp0A: 35.5	5yu9D-3pp0A: 59.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxf	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Toxoplasma gondii)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	VAL A 65 ALA A 78 LYS A 80 LEU A 181 ASP A 195 LEU A 198	BK5 A 701 (-4.2A) BK5 A 701 (-3.4A) BK5 A 701 (-3.5A) None BK5 A 701 (-4.0A) BK5 A 701 ( 4.9A)	0.63A	5yu9D-3sxfA: 23.8	5yu9D-3sxfA: 11.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 431 ALA A 443 LYS A 445 GLY A 495 CYH A 496 LEU A 543	PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) PP2 A 1 ( 4.2A) None PP2 A 1 (-4.6A)	0.77A	5yu9D-3sxsA: 29.4	5yu9D-3sxsA: 18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 303 ALA A 315 LYS A 317 GLY A 369 LEU A 423 ASP A 434	None	1.01A	5yu9D-3ulzA: 16.8	5yu9D-3ulzA: 15.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 83 ALA A 96 LYS A 98 GLY A 150 LEU A 198 ASP A 209	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.51A	5yu9D-3wigA: 24.0	5yu9D-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 83 ALA A 96 LYS A 98 MET A 144 GLY A 150 ASP A 153 LEU A 198	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) None ANP A 401 (-4.8A)	1.31A	5yu9D-3wigA: 24.0	5yu9D-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 848 ALA A 866 GLY A 922 LEU A1035 ASP A1046 LEU A1049	LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.4A) LEV A1201 ( 4.5A)	0.76A	5yu9D-3wzdA: 28.9	5yu9D-3wzdA: 14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 633 ALA A 649 LYS A 651 GLY A 703 LEU A 751 ASP A 762	None	0.88A	5yu9D-3zfxA: 31.0	5yu9D-3zfxA: 15.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 222 ALA A 233 GLY A 289 ASP A 293 LEU A 343 ASP A 354	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 (-3.5A) None TAK A1507 (-4.7A) TAK A1507 (-3.5A)	0.51A	5yu9D-4c02A: 24.7	5yu9D-4c02A: 15.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 222 ALA A 233 LYS A 235 GLY A 289 ASP A 293 ASP A 354	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) TAK A1507 (-3.5A) None TAK A1507 (-3.5A)	0.77A	5yu9D-4c02A: 24.7	5yu9D-4c02A: 15.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	6	VAL A 254 ALA A 267 GLY A 324 LEU A 371 THR A 381 ASP A 382	None	0.87A	5yu9D-4c0tA: 20.5	5yu9D-4c0tA: 7.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 575 ALA A 588 LYS A 590 GLY A 642 LEU A 690 ASP A 701	GUI A 901 (-4.5A) GUI A 901 (-3.4A) GUI A 901 (-2.8A) GUI A 901 (-3.5A) GUI A 901 (-4.3A) GUI A 901 ( 4.1A)	1.01A	5yu9D-4e93A: 30.6	5yu9D-4e93A: 13.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 385 ALA A 400 LYS A 402 GLY A 454 LEU A 501 ASP A 512	0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) 0SB A 701 (-3.5A) 0SB A 701 (-4.4A) 0SB A 701 (-3.9A)	0.86A	5yu9D-4f4pA: 28.3	5yu9D-4f4pA: 45.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fie	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF00786 (PBD)	6	VAL A 335 ALA A 348 LYS A 350 GLY A 401 LEU A 447 ASP A 458	ANP A1001 (-4.7A) ANP A1001 (-3.6A) ANP A1001 (-3.0A) None ANP A1001 (-4.7A) ANP A1001 (-2.7A)	0.86A	5yu9D-4fieA: 22.0	5yu9D-4fieA: 11.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	VAL A 385 ALA A 400 LYS A 402 MET A 424 GLY A 454 LEU A 501 ASP A 512 LEU A 515	ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) None ANP A 701 ( 4.2A) ANP A 701 (-4.5A) MG A 702 ( 3.1A) None	0.61A	5yu9D-4fl3A: 32.2	5yu9D-4fl3A: 7.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	VAL A 385 ALA A 400 LYS A 402 MET A 448 GLY A 454 LEU A 501 ASP A 512 LEU A 515	ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 ( 3.7A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A) MG A 702 ( 3.1A) None	0.83A	5yu9D-4fl3A: 32.2	5yu9D-4fl3A: 7.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g3f	NF-KAPPA-BETA-INDUCI NG KINASE (Mus musculus)	PF00069 (Pkinase)	5	VAL A 416 ALA A 429 MET A 471 GLY A 477 LEU A 524	0WB A 701 (-4.4A) 0WB A 701 (-3.3A) 0WB A 701 (-3.9A) 0WB A 701 ( 4.5A) 0WB A 701 (-4.3A)	0.45A	5yu9D-4g3fA: 23.6	5yu9D-4g3fA: 16.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 863 ALA A 880 GLY A 935 ASP A 939 LEU A 983 ASP A 994	None IZA A2001 (-3.4A) IZA A2001 (-3.3A) None IZA A2001 ( 4.7A) IZA A2001 ( 4.5A)	0.76A	5yu9D-4gl9A: 28.8	5yu9D-4gl9A: 15.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 836 ALA A 853 GLY A 908 CYH A 909 ASP A 912 LEU A 956	19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 ( 3.8A) None None 19S A1201 (-4.5A)	0.63A	5yu9D-4hviA: 29.8	5yu9D-4hviA: 13.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	7	VAL A 140 ALA A 156 LYS A 158 MET A 181 ASP A 215 ASP A 270 LEU A 273	None	0.78A	5yu9D-4hzsA: 31.8	5yu9D-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	8	VAL A 140 ALA A 156 MET A 181 GLY A 211 ASP A 215 LEU A 259 ASP A 270 LEU A 273	None	0.63A	5yu9D-4hzsA: 31.8	5yu9D-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 140 ALA A 156 LYS A 158 MET A 181 ASP A 215 LEU A 259	1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 (-4.0A) None 1G0 A 401 (-4.6A)	1.40A	5yu9D-4id7A: 25.0	5yu9D-4id7A: 15.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	VAL A 281 ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 348 LEU A 393 ASP A 404 LEU A 407	0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None 0J9 A 601 ( 4.1A) None 0J9 A 601 (-4.5A) 0J9 A 601 (-3.1A) None	0.69A	5yu9D-4k11A: 32.5	5yu9D-4k11A: 15.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 421 ALA A 434 GLY A 487 ASP A 491 LEU A 533	None B49 A 701 (-3.2A) B49 A 701 ( 3.7A) B49 A 701 ( 4.3A) B49 A 701 (-4.5A)	0.48A	5yu9D-4ks8A: 23.6	5yu9D-4ks8A: 14.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	VAL A 281 ALA A 293 LYS A 295 GLY A 344 ASP A 348 LEU A 393	VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 3.2A) None VGG A 601 (-4.5A)	0.70A	5yu9D-4lggA: 28.1	5yu9D-4lggA: 18.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	VAL A 281 ALA A 293 LYS A 295 GLY A 344 LEU A 393 ASP A 404	VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 3.2A) VGG A 601 (-4.5A) VGG A 601 ( 4.7A)	0.83A	5yu9D-4lggA: 28.1	5yu9D-4lggA: 18.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 ALA A 49 GLY A 101 LEU A 150 ASP A 161 LEU A 164	ANP A 401 (-4.5A) ANP A 401 (-3.1A) None ANP A 401 (-4.8A) MG A 403 ( 3.1A) None	0.78A	5yu9D-4m69A: 26.8	5yu9D-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 ALA A 49 LYS A 51 LEU A 150 ASP A 161 LEU A 164	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) ANP A 401 (-4.8A) MG A 403 ( 3.1A) None	0.71A	5yu9D-4m69A: 26.8	5yu9D-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 ALA A 49 LYS A 51 MET A 65 LEU A 150 LEU A 164	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) None ANP A 401 (-4.8A) None	1.02A	5yu9D-4m69A: 26.8	5yu9D-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 ALA A 49 MET A 65 GLY A 101 LEU A 150 LEU A 164	ANP A 401 (-4.5A) ANP A 401 (-3.1A) None None ANP A 401 (-4.8A) None	1.04A	5yu9D-4m69A: 26.8	5yu9D-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	6	VAL A 205 ALA A 218 LYS A 220 GLY A 277 LEU A 324 ASP A 335	29X A 702 (-4.7A) 29X A 702 (-3.1A) 29X A 702 (-3.6A) None 29X A 702 (-4.6A) 29X A 702 (-4.4A)	0.97A	5yu9D-4mk0A: 15.1	5yu9D-4mk0A: 7.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rgj	CALCIUM-DEPENDENT PROTEIN KINASE 4 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	VAL A 84 ALA A 97 LYS A 99 LEU A 200 ASP A 215 LEU A 218	None	0.87A	5yu9D-4rgjA: 23.4	5yu9D-4rgjA: 10.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4uy9	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 158 ALA A 169 LYS A 171 LEU A 275 THR A 293 ASP A 294	None	1.25A	5yu9D-4uy9A: 27.0	5yu9D-4uy9A: 13.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 LEU A 528 ASP A 539 LEU A 542	None	0.75A	5yu9D-4xi2A: 25.7	5yu9D-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 416 LYS A 430 MET A 449 CYH A 481 ASP A 539 LEU A 542	None	1.04A	5yu9D-4xi2A: 25.7	5yu9D-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 GLY A 480 CYH A 481 LEU A 528 ASP A 539	746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.6A) None 746 A 702 (-4.4A) 746 A 702 (-3.7A)	0.57A	5yu9D-4y93A: 30.6	5yu9D-4y93A: 10.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 LYS A 33 LEU A 135 ASP A 146 LEU A 149	None	0.72A	5yu9D-4yc6A: 24.2	5yu9D-4yc6A: 16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 492 ALA A 512 GLY A 567 LEU A 630 ASP A 641 LEU A 644	38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 (-3.4A) 38O A1769 (-4.6A) 38O A1769 (-4.0A) None	0.81A	5yu9D-5a46A: 28.7	5yu9D-5a46A: 12.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 492 ALA A 512 LYS A 514 LEU A 630 ASP A 641 LEU A 644	38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) 38O A1769 (-4.6A) 38O A1769 (-4.0A) None	1.11A	5yu9D-5a46A: 28.7	5yu9D-5a46A: 12.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 911 ALA A 928 GLY A 984 ASP A 988 LEU A1030 ASP A1041	5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) 5U3 A1200 (-3.2A) None 5U3 A1200 (-4.4A) 5U3 A1200 ( 4.9A)	0.88A	5yu9D-5f1zA: 28.4	5yu9D-5f1zA: 15.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 43 MET A 90 GLY A 96 LEU A 143 ASP A 154	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 (-3.5A) 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A) 6G2 A 901 (-3.4A)	0.91A	5yu9D-5j5tA: 21.8	5yu9D-5j5tA: 15.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 726 ALA A 743 LYS A 745 MET A 790 ASP A 800 LEU A 844 THR A 854	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.1A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A)	0.83A	5yu9D-5j9zA: 36.1	5yu9D-5j9zA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 726 ALA A 743 MET A 790 GLY A 796 CYH A 797 ASP A 800 LEU A 844 THR A 854 ASP A 855	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.5A) 6HJ A1101 (-1.6A) 6HJ A1101 ( 4.1A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A) 6HJ A1101 (-4.3A)	0.67A	5yu9D-5j9zA: 36.1	5yu9D-5j9zA: 95.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 284 ALA A 297 GLY A 350 ASP A 354 LEU A 396 THR A 406	IPW A 601 (-4.2A) IPW A 601 (-3.5A) IPW A 601 ( 3.8A) None IPW A 601 (-4.5A) IPW A 601 (-3.7A)	0.72A	5yu9D-5kbrA: 21.8	5yu9D-5kbrA: 17.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vil	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 (Homo sapiens)	no annotation	6	VAL A 694 ALA A 707 LYS A 709 MET A 754 ASP A 807 LEU A 722	9E1 A1001 ( 4.0A) 9E1 A1001 (-3.5A) 9E1 A1001 (-2.8A) 9E1 A1001 (-2.8A) None None	1.16A	5yu9D-5vilA: 24.0	5yu9D-5vilA: 26.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	VAL A 899 ALA A 917 GLY A 969 LEU A1017 THR A1027 ASP A1028	ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A) ANP A1201 ( 4.9A) MG A1202 ( 3.0A)	0.64A	5yu9D-5wnoA: 34.6	5yu9D-5wnoA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	VAL A 899 ALA A 917 LYS A 919 MET A 938 THR A1027 ASP A1028 LEU A1031	ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) None ANP A1201 ( 4.9A) MG A1202 ( 3.0A) None	1.05A	5yu9D-5wnoA: 34.6	5yu9D-5wnoA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	VAL A 899 ALA A 917 MET A 938 LEU A1017 THR A1027 ASP A1028	ANP A1201 (-4.4A) ANP A1201 (-3.3A) None ANP A1201 (-4.7A) ANP A1201 ( 4.9A) MG A1202 ( 3.0A)	0.81A	5yu9D-5wnoA: 34.6	5yu9D-5wnoA: 42.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	7	VAL A 212 ALA A 225 GLY A 279 ASP A 283 LEU A 326 THR A 338 ASP A 339	None	0.84A	5yu9D-5xzwA: 18.8	5yu9D-5xzwA: 10.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	VAL A 41 ALA A 54 LYS A 56 MET A 74 GLY A 105 LEU A 153 ASP A 164	ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) None ANP A 501 ( 4.0A) ANP A 501 (-4.6A) MG A 502 ( 3.1A)	0.83A	5yu9D-6ao5A: 23.7	5yu9D-6ao5A: 13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	VAL A 41 ALA A 54 LYS A 56 MET A 99 GLY A 105 LEU A 153 ASP A 164	ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) ANP A 501 (-2.5A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A) MG A 502 ( 3.1A)	0.77A	5yu9D-6ao5A: 23.7	5yu9D-6ao5A: 13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	no annotation	5	VAL A 226 ALA A 237 GLY A 294 LEU A 347 ASP A 358	None DL1 A 601 (-3.4A) DL1 A 601 (-3.5A) DL1 A 601 (-3.9A) DL1 A 601 (-3.1A)	0.49A	5yu9D-6bfnA: 23.1	5yu9D-6bfnA: 29.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	6	VAL A 205 ALA A 217 LYS A 219 MET A 239 GLY A 270 LEU A 333	FKY A9001 ( 4.6A) FKY A9001 (-3.3A) None FKY A9001 (-4.2A) FKY A9001 (-3.3A) None	1.27A	5yu9D-6cz4A: 22.2	5yu9D-6cz4A: 31.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6eqi	SERINE/THREONINE-PRO TEIN KINASE PINK1, PUTATIVE (Pediculus humanus)	no annotation	6	VAL C 173 ALA C 191 LYS C 193 MET C 290 THR C 356 ASP C 357	None	1.18A	5yu9D-6eqiC: 20.5	5yu9D-6eqiC: 12.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6eqi	SERINE/THREONINE-PRO TEIN KINASE PINK1, PUTATIVE (Pediculus humanus)	no annotation	6	VAL C 173 ALA C 191 MET C 290 LEU C 341 THR C 356 ASP C 357	None	0.89A	5yu9D-6eqiC: 20.5	5yu9D-6eqiC: 12.56

[["5YU9_D_1E8D1101_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.83A","5yu9D-1k2pA:28.8","5yu9D-1k2pA:14.77"],["5YU9_D_1E8D1101_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;GLY A 272;ASP A 276;LEU A 321;ASP A 332","None","0.79A","5yu9D-1k9aA:29.7","5yu9D-1k9aA:12.83"],["5YU9_D_1E8D1101_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",5,"VAL A 219;ALA A 230;GLY A 286;LEU A 340;ASP A 351","PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-3.6A);PY1 A 700 (-4.4A);PY1 A 700 (-2.7A)","0.47A","5yu9D-1py5A:24.7","5yu9D-1py5A:11.15"],["5YU9_D_1E8D1101_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"VAL A  86;ALA A  99;LYS A 101;MET A 147;ASP A 156;LEU A 201","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 ( 3.4A);None;ATP A 535 (-4.8A)","1.10A","5yu9D-1s9iA:16.2","5yu9D-1s9iA:15.71"],["5YU9_D_1E8D1101_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",7,"VAL A  86;ALA A  99;LYS A 101;MET A 147;GLY A 153;LEU A 201;ASP A 212","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 ( 3.4A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.77A","5yu9D-1s9iA:16.2","5yu9D-1s9iA:15.71"],["5YU9_D_1E8D1101_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;GLY A 441;CYH A 442;ASP A 445;LEU A 489;ASP A 500","None","0.63A","5yu9D-1snxA:23.0","5yu9D-1snxA:16.00"],["5YU9_D_1E8D1101_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",6,"VAL A 377;ALA A 389;LYS A 391;CYH A 442;ASP A 445;ASP A 500","None","0.91A","5yu9D-1snxA:23.0","5yu9D-1snxA:16.00"],["5YU9_D_1E8D1101_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"VAL X  25;ALA X  37;GLY X  88;ASP X  92;LEU X 137;ASP X 148","STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.5A);None;STU X 902 (-4.4A);STU X 902 (-3.6A)","0.82A","5yu9D-2dq7X:28.9","5yu9D-2dq7X:13.72"],["5YU9_D_1E8D1101_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"VAL A 281;ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 348;LEU A 393;ASP A 404;LEU A 407","H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);None;H8H A 534 (-3.3A);None;H8H A 534 (-4.5A);H8H A 534 (-4.2A);None","0.81A","5yu9D-2h8hA:32.4","5yu9D-2h8hA:12.89"],["5YU9_D_1E8D1101_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 348;ASP A 404","QUE A   1 (-3.5A);None;None;QUE A   1 (-3.0A);QUE A   1 ( 4.1A);None","1.07A","5yu9D-2hckA:30.6","5yu9D-2hckA:11.29"],["5YU9_D_1E8D1101_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;MET A 314;GLY A 344;ASP A 348;LEU A 393;ASP A 404","QUE A   1 (-3.5A);None;QUE A   1 (-3.0A);QUE A   1 ( 4.1A);QUE A   1 (-4.4A);None","0.81A","5yu9D-2hckA:30.6","5yu9D-2hckA:11.29"],["5YU9_D_1E8D1101_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 281;ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 404","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.0A);None","0.98A","5yu9D-2hckA:30.6","5yu9D-2hckA:11.29"],["5YU9_D_1E8D1101_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 281;ALA A 293;MET A 314;GLY A 344;LEU A 393;ASP A 404","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.0A);QUE A   1 (-4.4A);None","0.74A","5yu9D-2hckA:30.6","5yu9D-2hckA:11.29"],["5YU9_D_1E8D1101_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",5,"VAL A 259;ALA A 271;GLY A 322;ASP A 326;LEU A 371","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.5A);None;1BM A 499 (-4.4A)","0.49A","5yu9D-2hk5A:23.7","5yu9D-2hk5A:19.18"],["5YU9_D_1E8D1101_1","2owm","Neurospora crassa","RELATED TO KINESIN-LIKE PROTEIN KIF1C","PF00225(Kinesin)",6,"VAL A  43;ALA A 387;GLY A 125;ASP A 122;LEU A 163;THR A 153","None","1.37A","5yu9D-2owmA:undetectable","5yu9D-2owmA:11.87"],["5YU9_D_1E8D1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"VAL A 352;ALA A 367;LYS A 369;MET A 390;GLY A 420;LEU A 468;ASP A 479;LEU A 482","ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;ANP A 615 ( 3.9A);ANP A 615 (-4.7A); MG A 614 ( 3.2A);None","0.88A","5yu9D-2ozoA:30.9","5yu9D-2ozoA:8.25"],["5YU9_D_1E8D1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 352;ALA A 367;LYS A 369;MET A 390;MET A 414;GLY A 420","ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;ANP A 615 ( 3.9A);ANP A 615 ( 3.9A)","1.09A","5yu9D-2ozoA:30.9","5yu9D-2ozoA:8.25"],["5YU9_D_1E8D1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"VAL A 352;LYS A 369;MET A 390;GLY A 418;LEU A 468;ASP A 479;LEU A 482","ANP A 615 (-4.5A);ANP A 615 (-3.1A);None;ANP A 615 ( 4.0A);ANP A 615 (-4.7A); MG A 614 ( 3.2A);None","1.44A","5yu9D-2ozoA:30.9","5yu9D-2ozoA:8.25"],["5YU9_D_1E8D1101_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",5,"VAL A  33;ALA A  46;GLY A 109;LEU A 156;THR A 166","ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;ATP A 381 ( 4.8A);ATP A 381 ( 4.6A)","0.44A","5yu9D-2phkA:22.1","5yu9D-2phkA:17.20"],["5YU9_D_1E8D1101_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"VAL A 495;ALA A 515;LYS A 517;GLY A 570;LEU A 633;ASP A 644","None","0.97A","5yu9D-2psqA:28.8","5yu9D-2psqA:13.04"],["5YU9_D_1E8D1101_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL B  55;ALA B  67;LYS B  69;GLY B 120;LEU B 171;THR B 181","None","0.68A","5yu9D-2qkwB:22.4","5yu9D-2qkwB:15.38"],["5YU9_D_1E8D1101_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;GLY A 271;ASP A 275;LEU A 328;ASP A 339","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);ADE A 488 ( 4.1A);None;ADE A 488 (-4.4A);None","0.64A","5yu9D-2qluA:24.3","5yu9D-2qluA:14.33"],["5YU9_D_1E8D1101_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;LYS A 217;ASP A 275;LEU A 328;ASP A 339","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;None;ADE A 488 (-4.4A);None","0.86A","5yu9D-2qluA:24.3","5yu9D-2qluA:14.33"],["5YU9_D_1E8D1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LYS A 751;MET A 772;LEU A 850;THR A 860;ASP A 861;LEU A 864","GW7 A   1 (-3.9A);GW7 A   1 ( 3.8A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A);GW7 A   1 ( 4.7A)","0.85A","5yu9D-2r4bA:37.5","5yu9D-2r4bA:18.38"],["5YU9_D_1E8D1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"VAL A 732;ALA A 749;GLY A 802;LEU A 850;THR A 860;LEU A 864","GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 ( 4.7A)","0.73A","5yu9D-2r4bA:37.5","5yu9D-2r4bA:18.38"],["5YU9_D_1E8D1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",7,"VAL A 732;ALA A 749;LYS A 751;LEU A 850;THR A 860;ASP A 861;LEU A 864","GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A);GW7 A   1 ( 4.7A)","0.74A","5yu9D-2r4bA:37.5","5yu9D-2r4bA:18.38"],["5YU9_D_1E8D1101_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",6,"VAL A 234;ALA A 247;GLY A 307;ASP A 311;LEU A 354;THR A 367","XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 ( 3.7A);None;XK9 A1511 (-4.6A);XK9 A1511 (-3.7A)","0.54A","5yu9D-2xk9A:20.8","5yu9D-2xk9A:14.85"],["5YU9_D_1E8D1101_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",6,"VAL A 234;ALA A 247;LYS A 249;GLY A 307;ASP A 311;LEU A 354","XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.2A);XK9 A1511 ( 3.7A);None;XK9 A1511 (-4.6A)","0.85A","5yu9D-2xk9A:20.8","5yu9D-2xk9A:14.85"],["5YU9_D_1E8D1101_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",6,"VAL A  38;ALA A  51;GLY A 113;ASP A 117;LEU A 160;ASP A 171","None;B49 A1294 (-3.2A);B49 A1294 (-3.6A);None;B49 A1294 (-4.4A);B49 A1294 (-4.2A)","0.69A","5yu9D-2y7jA:22.5","5yu9D-2y7jA:13.22"],["5YU9_D_1E8D1101_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",6,"VAL A 261;ALA A 273;LYS A 275;GLY A 325;ASP A 329;LEU A 374","None","0.80A","5yu9D-2zv7A:25.9","5yu9D-2zv7A:18.80"],["5YU9_D_1E8D1101_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;GLY A 272;ASP A 276;LEU A 321;ASP A 332","None","0.79A","5yu9D-3d7uA:24.2","5yu9D-3d7uA:19.23"],["5YU9_D_1E8D1101_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",6,"VAL A  31;ALA A  44;LYS A  46;MET A  67;ASP A 102;ASP A 164","ANP A   1 (-4.5A);ANP A   1 ( 3.9A);ANP A   1 (-2.8A);None;None;ANP A   1 (-3.8A)","1.01A","5yu9D-3dakA:22.7","5yu9D-3dakA:15.25"],["5YU9_D_1E8D1101_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",6,"VAL A  31;ALA A  44;LYS A  46;MET A  92;ASP A 102;ASP A 164","ANP A   1 (-4.5A);ANP A   1 ( 3.9A);ANP A   1 (-2.8A);None;None;ANP A   1 (-3.8A)","1.26A","5yu9D-3dakA:22.7","5yu9D-3dakA:15.25"],["5YU9_D_1E8D1101_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",6,"VAL A  31;ALA A  44;MET A  67;GLY A  98;LEU A 153;ASP A 164","ANP A   1 (-4.5A);ANP A   1 ( 3.9A);None;None;None;ANP A   1 (-3.8A)","0.84A","5yu9D-3dakA:22.7","5yu9D-3dakA:15.25"],["5YU9_D_1E8D1101_1","3dtc","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF07714(Pkinase_Tyr)",5,"VAL A 158;ALA A 169;GLY A 226;LEU A 275;THR A 293","VIN A6331 (-4.7A);VIN A6331 (-3.4A);VIN A6331 (-3.4A);VIN A6331 (-4.5A);VIN A6331 (-3.6A)","0.47A","5yu9D-3dtcA:19.6","5yu9D-3dtcA:14.45"],["5YU9_D_1E8D1101_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",6,"VAL A  37;ALA A  50;GLY A 106;LEU A 153;ASP A 167;LEU A 170","None","0.68A","5yu9D-3dxnA:24.9","5yu9D-3dxnA:14.98"],["5YU9_D_1E8D1101_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",6,"VAL A  37;ALA A  50;MET A 100;ASP A 110;LEU A 153;ASP A 167","None","0.97A","5yu9D-3dxnA:24.9","5yu9D-3dxnA:14.98"],["5YU9_D_1E8D1101_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",6,"VAL A  37;ALA A  50;MET A 100;LEU A 153;ASP A 167;LEU A 170","None","0.93A","5yu9D-3dxnA:24.9","5yu9D-3dxnA:14.98"],["5YU9_D_1E8D1101_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",6,"VAL A 439;ALA A 455;LYS A 457;GLY A 508;LEU A 556;ASP A 567","AGS A 999 (-4.6A);AGS A 999 (-3.6A);AGS A 999 (-2.5A);None;AGS A 999 (-4.5A);AGS A 999 ( 3.9A)","0.94A","5yu9D-3fzpA:29.9","5yu9D-3fzpA:18.35"],["5YU9_D_1E8D1101_1","3g2f","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2","PF00069(Pkinase)",6,"VAL A 217;ALA A 228;LYS A 230;MET A 279;GLY A 285;LEU A 340","ADP A 900 (-4.3A);ADP A 900 (-3.4A);ADP A 900 (-2.8A);ADP A 900 (-3.6A);ADP A 900 ( 4.2A);ADP A 900 (-4.6A)","0.79A","5yu9D-3g2fA:24.7","5yu9D-3g2fA:13.21"],["5YU9_D_1E8D1101_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",6,"ALA A 247;GLY A 307;ASP A 311;LEU A 354;THR A 367;ASP A 368","None","0.79A","5yu9D-3i6uA:22.4","5yu9D-3i6uA:10.83"],["5YU9_D_1E8D1101_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",6,"VAL A 704;LYS A 723;GLY A 774;ASP A 778;LEU A 822;ASP A 833","ANP A   1 (-3.9A);ANP A   1 (-3.4A);ANP A   1 ( 4.9A);None;ANP A   1 (-4.7A); MG A1001 ( 3.1A)","0.81A","5yu9D-3kexA:30.4","5yu9D-3kexA:15.79"],["5YU9_D_1E8D1101_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",10,"ALA A 719;LYS A 721;MET A 742;GLY A 772;CYH A 773;ASP A 776;LEU A 820;THR A 830;ASP A 831;LEU A 834","ITI A   1 (-2.9A);ITI A   1 (-2.6A);ITI A   1 (-3.4A);ITI A   1 (-3.5A);ITI A   1 (-4.8A);None;ITI A   1 (-4.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.6A);None","0.79A","5yu9D-3lzbA:39.0","5yu9D-3lzbA:95.00"],["5YU9_D_1E8D1101_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",10,"VAL A 702;ALA A 719;LYS A 721;MET A 742;CYH A 773;ASP A 776;LEU A 820;THR A 830;ASP A 831;LEU A 834","ITI A   1 (-4.8A);ITI A   1 (-2.9A);ITI A   1 (-2.6A);ITI A   1 (-3.4A);ITI A   1 (-4.8A);None;ITI A   1 (-4.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.6A);None","0.80A","5yu9D-3lzbA:39.0","5yu9D-3lzbA:95.00"],["5YU9_D_1E8D1101_1","3pls","Homo sapiens","MACROPHAGE-STIMULATING PROTEIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A1096;ALA A1112;LYS A1114;GLY A1167;ASP A1226;LEU A1229","ANP A1358 (-4.4A);ANP A1358 ( 3.8A);ANP A1358 (-3.2A);None; MG A   1 ( 3.2A);None","0.65A","5yu9D-3plsA:31.3","5yu9D-3plsA:16.03"],["5YU9_D_1E8D1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",8,"VAL A 734;ALA A 751;MET A 774;GLY A 804;CYH A 805;ASP A 808;LEU A 852;THR A 862","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.5A);03Q A   1 ( 3.9A);None;None;03Q A   1 (-4.4A);03Q A   1 (-3.3A)","1.33A","5yu9D-3pp0A:35.5","5yu9D-3pp0A:59.82"],["5YU9_D_1E8D1101_1","3sxf","Toxoplasma gondii","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase);PF13499(EF-hand_7)",6,"VAL A  65;ALA A  78;LYS A  80;LEU A 181;ASP A 195;LEU A 198","BK5 A 701 (-4.2A);BK5 A 701 (-3.4A);BK5 A 701 (-3.5A);None;BK5 A 701 (-4.0A);BK5 A 701 ( 4.9A)","0.63A","5yu9D-3sxfA:23.8","5yu9D-3sxfA:11.36"],["5YU9_D_1E8D1101_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"VAL A 431;ALA A 443;LYS A 445;GLY A 495;CYH A 496;LEU A 543","PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);PP2 A   1 ( 4.2A);None;PP2 A   1 (-4.6A)","0.77A","5yu9D-3sxsA:29.4","5yu9D-3sxsA:18.02"],["5YU9_D_1E8D1101_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",6,"VAL A 303;ALA A 315;LYS A 317;GLY A 369;LEU A 423;ASP A 434","None","1.01A","5yu9D-3ulzA:16.8","5yu9D-3ulzA:15.44"],["5YU9_D_1E8D1101_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",6,"VAL A  83;ALA A  96;LYS A  98;GLY A 150;LEU A 198;ASP A 209","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.51A","5yu9D-3wigA:24.0","5yu9D-3wigA:16.55"],["5YU9_D_1E8D1101_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"VAL A  83;ALA A  96;LYS A  98;MET A 144;GLY A 150;ASP A 153;LEU A 198","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);None;ANP A 401 (-4.8A)","1.31A","5yu9D-3wigA:24.0","5yu9D-3wigA:16.55"],["5YU9_D_1E8D1101_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"VAL A 848;ALA A 866;GLY A 922;LEU A1035;ASP A1046;LEU A1049","LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.4A);LEV A1201 ( 4.5A)","0.76A","5yu9D-3wzdA:28.9","5yu9D-3wzdA:14.29"],["5YU9_D_1E8D1101_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"VAL A 633;ALA A 649;LYS A 651;GLY A 703;LEU A 751;ASP A 762","None","0.88A","5yu9D-3zfxA:31.0","5yu9D-3zfxA:15.35"],["5YU9_D_1E8D1101_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 222;ALA A 233;GLY A 289;ASP A 293;LEU A 343;ASP A 354","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 (-3.5A);None;TAK A1507 (-4.7A);TAK A1507 (-3.5A)","0.51A","5yu9D-4c02A:24.7","5yu9D-4c02A:15.41"],["5YU9_D_1E8D1101_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 222;ALA A 233;LYS A 235;GLY A 289;ASP A 293;ASP A 354","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);TAK A1507 (-3.5A);None;TAK A1507 (-3.5A)","0.77A","5yu9D-4c02A:24.7","5yu9D-4c02A:15.41"],["5YU9_D_1E8D1101_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",6,"VAL A 254;ALA A 267;GLY A 324;LEU A 371;THR A 381;ASP A 382","None","0.87A","5yu9D-4c0tA:20.5","5yu9D-4c0tA:7.37"],["5YU9_D_1E8D1101_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 575;ALA A 588;LYS A 590;GLY A 642;LEU A 690;ASP A 701","GUI A 901 (-4.5A);GUI A 901 (-3.4A);GUI A 901 (-2.8A);GUI A 901 (-3.5A);GUI A 901 (-4.3A);GUI A 901 ( 4.1A)","1.01A","5yu9D-4e93A:30.6","5yu9D-4e93A:13.45"],["5YU9_D_1E8D1101_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"VAL A 385;ALA A 400;LYS A 402;GLY A 454;LEU A 501;ASP A 512","0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);0SB A 701 (-3.5A);0SB A 701 (-4.4A);0SB A 701 (-3.9A)","0.86A","5yu9D-4f4pA:28.3","5yu9D-4f4pA:45.71"],["5YU9_D_1E8D1101_1","4fie","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF00786(PBD)",6,"VAL A 335;ALA A 348;LYS A 350;GLY A 401;LEU A 447;ASP A 458","ANP A1001 (-4.7A);ANP A1001 (-3.6A);ANP A1001 (-3.0A);None;ANP A1001 (-4.7A);ANP A1001 (-2.7A)","0.86A","5yu9D-4fieA:22.0","5yu9D-4fieA:11.19"],["5YU9_D_1E8D1101_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"VAL A 385;ALA A 400;LYS A 402;MET A 424;GLY A 454;LEU A 501;ASP A 512;LEU A 515","ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);None;ANP A 701 ( 4.2A);ANP A 701 (-4.5A); MG A 702 ( 3.1A);None","0.61A","5yu9D-4fl3A:32.2","5yu9D-4fl3A:7.85"],["5YU9_D_1E8D1101_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"VAL A 385;ALA A 400;LYS A 402;MET A 448;GLY A 454;LEU A 501;ASP A 512;LEU A 515","ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 ( 3.7A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A); MG A 702 ( 3.1A);None","0.83A","5yu9D-4fl3A:32.2","5yu9D-4fl3A:7.85"],["5YU9_D_1E8D1101_1","4g3f","Mus musculus","NF-KAPPA-BETA-INDUCING KINASE","PF00069(Pkinase)",5,"VAL A 416;ALA A 429;MET A 471;GLY A 477;LEU A 524","0WB A 701 (-4.4A);0WB A 701 (-3.3A);0WB A 701 (-3.9A);0WB A 701 ( 4.5A);0WB A 701 (-4.3A)","0.45A","5yu9D-4g3fA:23.6","5yu9D-4g3fA:16.93"],["5YU9_D_1E8D1101_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL A 863;ALA A 880;GLY A 935;ASP A 939;LEU A 983;ASP A 994","None;IZA A2001 (-3.4A);IZA A2001 (-3.3A);None;IZA A2001 ( 4.7A);IZA A2001 ( 4.5A)","0.76A","5yu9D-4gl9A:28.8","5yu9D-4gl9A:15.99"],["5YU9_D_1E8D1101_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"VAL A 836;ALA A 853;GLY A 908;CYH A 909;ASP A 912;LEU A 956","19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 ( 3.8A);None;None;19S A1201 (-4.5A)","0.63A","5yu9D-4hviA:29.8","5yu9D-4hviA:13.27"],["5YU9_D_1E8D1101_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",7,"VAL A 140;ALA A 156;LYS A 158;MET A 181;ASP A 215;ASP A 270;LEU A 273","None","0.78A","5yu9D-4hzsA:31.8","5yu9D-4hzsA:13.99"],["5YU9_D_1E8D1101_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",8,"VAL A 140;ALA A 156;MET A 181;GLY A 211;ASP A 215;LEU A 259;ASP A 270;LEU A 273","None","0.63A","5yu9D-4hzsA:31.8","5yu9D-4hzsA:13.99"],["5YU9_D_1E8D1101_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"VAL A 140;ALA A 156;LYS A 158;MET A 181;ASP A 215;LEU A 259","1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 (-4.0A);None;1G0 A 401 (-4.6A)","1.40A","5yu9D-4id7A:25.0","5yu9D-4id7A:15.60"],["5YU9_D_1E8D1101_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"VAL A 281;ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 348;LEU A 393;ASP A 404;LEU A 407","0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;0J9 A 601 ( 4.1A);None;0J9 A 601 (-4.5A);0J9 A 601 (-3.1A);None","0.69A","5yu9D-4k11A:32.5","5yu9D-4k11A:15.57"],["5YU9_D_1E8D1101_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",5,"VAL A 421;ALA A 434;GLY A 487;ASP A 491;LEU A 533","None;B49 A 701 (-3.2A);B49 A 701 ( 3.7A);B49 A 701 ( 4.3A);B49 A 701 (-4.5A)","0.48A","5yu9D-4ks8A:23.6","5yu9D-4ks8A:14.19"],["5YU9_D_1E8D1101_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"VAL A 281;ALA A 293;LYS A 295;GLY A 344;ASP A 348;LEU A 393","VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 3.2A);None;VGG A 601 (-4.5A)","0.70A","5yu9D-4lggA:28.1","5yu9D-4lggA:18.80"],["5YU9_D_1E8D1101_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"VAL A 281;ALA A 293;LYS A 295;GLY A 344;LEU A 393;ASP A 404","VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 3.2A);VGG A 601 (-4.5A);VGG A 601 ( 4.7A)","0.83A","5yu9D-4lggA:28.1","5yu9D-4lggA:18.80"],["5YU9_D_1E8D1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;ALA A  49;GLY A 101;LEU A 150;ASP A 161;LEU A 164","ANP A 401 (-4.5A);ANP A 401 (-3.1A);None;ANP A 401 (-4.8A); MG A 403 ( 3.1A);None","0.78A","5yu9D-4m69A:26.8","5yu9D-4m69A:14.43"],["5YU9_D_1E8D1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;ALA A  49;LYS A  51;LEU A 150;ASP A 161;LEU A 164","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);ANP A 401 (-4.8A); MG A 403 ( 3.1A);None","0.71A","5yu9D-4m69A:26.8","5yu9D-4m69A:14.43"],["5YU9_D_1E8D1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;ALA A  49;LYS A  51;MET A  65;LEU A 150;LEU A 164","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;ANP A 401 (-4.8A);None","1.02A","5yu9D-4m69A:26.8","5yu9D-4m69A:14.43"],["5YU9_D_1E8D1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;ALA A  49;MET A  65;GLY A 101;LEU A 150;LEU A 164","ANP A 401 (-4.5A);ANP A 401 (-3.1A);None;None;ANP A 401 (-4.8A);None","1.04A","5yu9D-4m69A:26.8","5yu9D-4m69A:14.43"],["5YU9_D_1E8D1101_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",6,"VAL A 205;ALA A 218;LYS A 220;GLY A 277;LEU A 324;ASP A 335","29X A 702 (-4.7A);29X A 702 (-3.1A);29X A 702 (-3.6A);None;29X A 702 (-4.6A);29X A 702 (-4.4A)","0.97A","5yu9D-4mk0A:15.1","5yu9D-4mk0A:7.84"],["5YU9_D_1E8D1101_1","4rgj","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 4","PF00069(Pkinase);PF13499(EF-hand_7)",6,"VAL A  84;ALA A  97;LYS A  99;LEU A 200;ASP A 215;LEU A 218","None","0.87A","5yu9D-4rgjA:23.4","5yu9D-4rgjA:10.40"],["5YU9_D_1E8D1101_1","4uy9","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF00069(Pkinase)",6,"VAL A 158;ALA A 169;LYS A 171;LEU A 275;THR A 293;ASP A 294","None","1.25A","5yu9D-4uy9A:27.0","5yu9D-4uy9A:13.70"],["5YU9_D_1E8D1101_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;LEU A 528;ASP A 539;LEU A 542","None","0.75A","5yu9D-4xi2A:25.7","5yu9D-4xi2A:11.21"],["5YU9_D_1E8D1101_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 416;LYS A 430;MET A 449;CYH A 481;ASP A 539;LEU A 542","None","1.04A","5yu9D-4xi2A:25.7","5yu9D-4xi2A:11.21"],["5YU9_D_1E8D1101_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;GLY A 480;CYH A 481;LEU A 528;ASP A 539","746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.6A);None;746 A 702 (-4.4A);746 A 702 (-3.7A)","0.57A","5yu9D-4y93A:30.6","5yu9D-4y93A:10.73"],["5YU9_D_1E8D1101_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;LYS A  33;LEU A 135;ASP A 146;LEU A 149","None","0.72A","5yu9D-4yc6A:24.2","5yu9D-4yc6A:16.67"],["5YU9_D_1E8D1101_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"VAL A 492;ALA A 512;GLY A 567;LEU A 630;ASP A 641;LEU A 644","38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 (-3.4A);38O A1769 (-4.6A);38O A1769 (-4.0A);None","0.81A","5yu9D-5a46A:28.7","5yu9D-5a46A:12.01"],["5YU9_D_1E8D1101_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"VAL A 492;ALA A 512;LYS A 514;LEU A 630;ASP A 641;LEU A 644","38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 ( 3.1A);38O A1769 (-4.6A);38O A1769 (-4.0A);None","1.11A","5yu9D-5a46A:28.7","5yu9D-5a46A:12.01"],["5YU9_D_1E8D1101_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"VAL A 911;ALA A 928;GLY A 984;ASP A 988;LEU A1030;ASP A1041","5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);5U3 A1200 (-3.2A);None;5U3 A1200 (-4.4A);5U3 A1200 ( 4.9A)","0.88A","5yu9D-5f1zA:28.4","5yu9D-5f1zA:15.10"],["5YU9_D_1E8D1101_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"VAL A  30;ALA A  43;MET A  90;GLY A  96;LEU A 143;ASP A 154","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 (-3.5A);6G2 A 901 (-3.6A);6G2 A 901 (-4.7A);6G2 A 901 (-3.4A)","0.91A","5yu9D-5j5tA:21.8","5yu9D-5j5tA:15.07"],["5YU9_D_1E8D1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 726;ALA A 743;LYS A 745;MET A 790;ASP A 800;LEU A 844;THR A 854","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.1A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A)","0.83A","5yu9D-5j9zA:36.1","5yu9D-5j9zA:95.00"],["5YU9_D_1E8D1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",9,"VAL A 726;ALA A 743;MET A 790;GLY A 796;CYH A 797;ASP A 800;LEU A 844;THR A 854;ASP A 855","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.5A);6HJ A1101 (-1.6A);6HJ A1101 ( 4.1A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A);6HJ A1101 (-4.3A)","0.67A","5yu9D-5j9zA:36.1","5yu9D-5j9zA:95.00"],["5YU9_D_1E8D1101_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",6,"VAL A 284;ALA A 297;GLY A 350;ASP A 354;LEU A 396;THR A 406","IPW A 601 (-4.2A);IPW A 601 (-3.5A);IPW A 601 ( 3.8A);None;IPW A 601 (-4.5A);IPW A 601 (-3.7A)","0.72A","5yu9D-5kbrA:21.8","5yu9D-5kbrA:17.15"],["5YU9_D_1E8D1101_1","5vil","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5","no annotation",6,"VAL A 694;ALA A 707;LYS A 709;MET A 754;ASP A 807;LEU A 722","9E1 A1001 ( 4.0A);9E1 A1001 (-3.5A);9E1 A1001 (-2.8A);9E1 A1001 (-2.8A);None;None","1.16A","5yu9D-5vilA:24.0","5yu9D-5vilA:26.19"],["5YU9_D_1E8D1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"VAL A 899;ALA A 917;GLY A 969;LEU A1017;THR A1027;ASP A1028","ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A);ANP A1201 ( 4.9A); MG A1202 ( 3.0A)","0.64A","5yu9D-5wnoA:34.6","5yu9D-5wnoA:42.68"],["5YU9_D_1E8D1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"VAL A 899;ALA A 917;LYS A 919;MET A 938;THR A1027;ASP A1028;LEU A1031","ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);None;ANP A1201 ( 4.9A); MG A1202 ( 3.0A);None","1.05A","5yu9D-5wnoA:34.6","5yu9D-5wnoA:42.68"],["5YU9_D_1E8D1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"VAL A 899;ALA A 917;MET A 938;LEU A1017;THR A1027;ASP A1028","ANP A1201 (-4.4A);ANP A1201 (-3.3A);None;ANP A1201 (-4.7A);ANP A1201 ( 4.9A); MG A1202 ( 3.0A)","0.81A","5yu9D-5wnoA:34.6","5yu9D-5wnoA:42.68"],["5YU9_D_1E8D1101_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",7,"VAL A 212;ALA A 225;GLY A 279;ASP A 283;LEU A 326;THR A 338;ASP A 339","None","0.84A","5yu9D-5xzwA:18.8","5yu9D-5xzwA:10.40"],["5YU9_D_1E8D1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"VAL A  41;ALA A  54;LYS A  56;MET A  74;GLY A 105;LEU A 153;ASP A 164","ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);None;ANP A 501 ( 4.0A);ANP A 501 (-4.6A); MG A 502 ( 3.1A)","0.83A","5yu9D-6ao5A:23.7","5yu9D-6ao5A:13.95"],["5YU9_D_1E8D1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"VAL A  41;ALA A  54;LYS A  56;MET A  99;GLY A 105;LEU A 153;ASP A 164","ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);ANP A 501 (-2.5A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A); MG A 502 ( 3.1A)","0.77A","5yu9D-6ao5A:23.7","5yu9D-6ao5A:13.95"],["5YU9_D_1E8D1101_1","6bfn","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1","no annotation",5,"VAL A 226;ALA A 237;GLY A 294;LEU A 347;ASP A 358","None;DL1 A 601 (-3.4A);DL1 A 601 (-3.5A);DL1 A 601 (-3.9A);DL1 A 601 (-3.1A)","0.49A","5yu9D-6bfnA:23.1","5yu9D-6bfnA:29.07"],["5YU9_D_1E8D1101_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",6,"VAL A 205;ALA A 217;LYS A 219;MET A 239;GLY A 270;LEU A 333","FKY A9001 ( 4.6A);FKY A9001 (-3.3A);None;FKY A9001 (-4.2A);FKY A9001 (-3.3A);None","1.27A","5yu9D-6cz4A:22.2","5yu9D-6cz4A:31.91"],["5YU9_D_1E8D1101_1","6eqi","Pediculus humanus","SERINE\/THREONINE-PROTEIN KINASE PINK1, PUTATIVE","no annotation",6,"VAL C 173;ALA C 191;LYS C 193;MET C 290;THR C 356;ASP C 357","None","1.18A","5yu9D-6eqiC:20.5","5yu9D-6eqiC:12.56"],["5YU9_D_1E8D1101_1","6eqi","Pediculus humanus","SERINE\/THREONINE-PROTEIN KINASE PINK1, PUTATIVE","no annotation",6,"VAL C 173;ALA C 191;MET C 290;LEU C 341;THR C 356;ASP C 357","None","0.89A","5yu9D-6eqiC:20.5","5yu9D-6eqiC:12.56"]]